Vitamin K2 MK-7 shows no recovery benefit, but potential for older adults' neuromuscular function
A recent 12-week RCT on vitamin K2 MK-7 revealed no impact on muscle recovery in healthy adults, challenging some market claims; however, a specific improvement in neuromuscular signalling was observed in older participants, suggesting a niche application opportunity.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 24 April 2026
A recent 12-week randomised controlled trial (RCT) has challenged perceptions regarding the efficacy of vitamin K2 MK-7 in exercise recovery. The study, detailed in NutraIngredients, investigated supplementation effects on neuromuscular function in healthy adults across two distinct age cohorts: 18-40 years and 65+ years. Crucially, the research found no significant impact on muscle strength or soreness recovery across the entire participant group, potentially necessitating a review of existing product claims by brand owners positioning K2 for post-exercise restoration.
Despite the overall lack of recovery benefit, a specific, commercially relevant finding emerged within the older adult cohort (65+ years). These participants demonstrated improved neuromuscular signalling, characterised by a reduced electromechanical delay post-supplementation. This indicates a potential role for vitamin K2 MK-7 in enhancing the neural-to-muscle communication pathway in ageing populations. This specific mechanism is distinct from direct muscle repair or anti-inflammatory effects and may offer a new angle for product development targeting age-related neuromuscular decline.
The trial's findings suggest that while K2 MK-7 may not be a broad-spectrum athletic recovery aid, its specific influence on neural communication in older adults warrants closer inspection. The underlying mechanisms for this effect remain undefined, indicating a need for further scientific exploration. Moreover, researchers highlighted a gap in understanding for the 40-65 age demographic, suggesting future studies should bridge this knowledge gap to fully delineate K2's age-specific benefits.
What this means for United Kingdom
UK brand owners relying on K2 MK-7's perceived exercise recovery benefits must reconcile product messaging with new clinical evidence, particularly given the Advertising Standards Authority's scrutiny. Formulators could explore repositioning K2 for the 65+ demographic, emphasising substantiated benefits in neuromuscular signalling to capture a growing healthy ageing market. This offers a differentiation point against competitors focused on general bone or cardiovascular health. Procurement leads should assess raw material investment based on redefined target demographics and potential reformulation windows, ensuring compliance and market relevance.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.